%201.png)
Key Takeaways
- Stargardt disease is entering a new era as therapies move closer to approval.
- Nearly every therapeutic program depends on identifying disease-causing ABCA4 variants through genetic testing.
- GeneDx Infinity includes one of the largest genetically characterized Stargardt cohorts, linking genomic, phenotypic, EHR, and claims data.
- These data can help biopharma improve patient identification, trial feasibility, and therapeutic development.
Why Stargardt disease research is entering a new era
After decades with no approved treatments, a wave of new therapies is finally arriving for the most common inherited macular dystrophy and nearly all of them start with identifying the genetic cause.
Stargardt disease usually begins early, in childhood or adolescence, with the gradual loss of central vision. It is the most common form of inherited macular dystrophy, affecting an estimated 1 in 8,000 to 10,000 people. Historically, the diagnosis came with a hard reality: no approved treatment, and no way to restore vision already lost.
That is changing quickly. In early June 2026, the first New Drug Application for a Stargardt therapy was completed with the U.S. Food and Drug Administration, with a deep pipeline of gene therapies, RNA-editing, and pharmacological approaches now in active clinical trials. Nearly all share one entry requirement: confirmation of disease-causing variants in the ABCA4 gene. What accelerates these programs is genetic findings linked to how patients are diagnosed, treated, and followed over time.
Genetic testing and genetically characterized patient data are central to the next phase of Stargardt research and treatment. GeneDx Infinity™ includes more than 500 individuals with two pathogenic or likely pathogenic ABCA4 variants, a genetically characterized cohort with the scale, variant-level detail, and linked phenotype, EHR, and claims data that therapeutic programs increasingly need.
Treatments are arriving — and they start with an accurate genetic diagnosis
For decades, Stargardt care and management consisted only of low-vision aids (such as electronic magnifiers or screen readers) and measures for preventing disease progression, such as limiting Vitamin-A intake and reducing sun exposure. Today treatment looks different and more hopeful. A once-daily oral therapy designed to slow disease progression completed a New Drug Application (NDA) with the FDA in June 2026 under Breakthrough Therapy Designation — potentially the first approved treatment for the disease.
What the GeneDx data shows
Within GeneDx Infinity™, the genetically characterized Stargardt cohort reflects the population these programs are trying to reach.
Key data — GeneDx Infinity™ Stargardt cohort
More than 500 — individuals with two pathogenic or likely pathogenic ABCA4 variants
Source: GeneDx Infinity™, June 2026.
The cohort is geographically broad, including 37 states and territories. The mean current age is 33, for patients who are identifiable today and reachable for trials now. As therapies move toward approval, that combination of scale, genetic characterization, and reach becomes increasingly valuable.
While symptoms typically begin in childhood or adolescence, the median age at genetic testing was 31 — suggesting that genetic characterization often arrives years after vision changes first appear. As therapies move toward approval, closing that gap becomes increasingly consequential.
ABCA4 is one of the hardest genes to interpret
More than 2,200 disease-causing variants have been described — from protein-truncating changes to deep-intronic variants tucked into stretches of the gene that routine testing skips and hypomorphic variants that weaken the gene rather than disable it, which are both easy to miss. Establishing that two variants together explain a patient’s disease demands real expertise and the most accurate exome or genome sequencing.
That difficulty has a practical consequence for trials. Most require two pathogenic or likely pathogenic ABCA4 variants, but in a meaningful share of patients the second variant is elusive, hidden in regions that are hard to sequence or interpret. Some trials have now loosened that requirement, allowing enrollment with a single identified variant for exactly this reason. Linking genetic data to detailed phenotype, as GeneDx Infinity™ does, can help characterize this single-variant subgroup — identifying patients whose clinical picture is consistent with ABCA4 disease even when the second variant remains unconfirmed.
How GeneDx Infinity™ supports Stargardt research
GeneDx Infinity™ begins with genomic sequencing and layers phenotypic and longitudinal EHR and claims data on top, connecting a genetic finding to a patient’s real-world diagnostic and treatment journey. For Stargardt programs, that means a single source for:
- Genetically characterized cohorts — individuals with defined ABCA4 genotypes, including biallelic and single-variant subgroups
- Variant-level detail — the specific ABCA4 variants identified, supporting genotype–phenotype analysis
- Demographics and geography — sex, age, and geographic distribution for feasibility and site planning
- Longitudinal claims & EHR data — real-world signals on diagnosis, treatment, and outcomes linked to each genetic finding, supporting natural-history, unmet need, and trial design
- Scale and expertise — a substantial genetically characterized Stargardt population, interpreted by a team with deep experience in a difficult gene
For biopharma partners developing Stargardt therapies, this supports the questions that determine whether a program can find and enroll the right patients: feasibility, trial design, patient identification, and natural-history understanding.
Looking ahead
Stargardt disease has moved from a condition with no treatment to one with a credible and growing pipeline. The constant across that shift is genetic diagnosis: it defines who has the disease, which variants they carry, and which therapies they may be eligible for. GeneDx brings both the testing depth to accurately characterize one of the most complex genes in inherited retinal disease and the real-world data needed to understand these patients at scale — helping biopharma teams find the right patients, design stronger studies, and move Stargardt therapies closer to the people who need them. Read how this same approach is supporting research in inherited cardiomyopathies.
